Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Yusuke Tomita(Northwestern University), Isao Date(Okayama University Hospital), Yuji Matsumoto(Meijo Hospital), Kentaro Fujii(Yokufukai Hospital), Atsuhito Uneda(Okayama University), Balveen Kaur(Augusta University), Yoshihiro Otani(Okayama University), Yasuhiko Hattori(Okayama University), Kazuhiko Kurozumi(Okayama University), Tomotsugu Ichikawa, Toshihiko Shimizu(The University of Texas Health Science Center), Tetsuo Oka(Okayama University), Ji Young Yoo(The University of Texas MD Anderson Cancer Center)
Cited by 35
Related Papers
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
|Proceedings of the National Academy of Sciences|2006|360
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth
|Cancer Cell|2015|336
Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
|Clinical Cancer Research|2016|332
VEGF-specific Short Hairpin RNA–expressing Oncolytic Adenovirus Elicits Potent Inhibition of Angiogenesis and Tumor Growth
|Molecular Therapy|2007|150
RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21
|Molecular Therapy|2017|147